DESTIN, Fla. — Systemic lupus erythematosus may benefit from being redefined and further subdivided, depending on the autoantibody profile of the patient, according to a speaker at the Congress of Clinical Rheumatology East 2022.
“I think it is very important when you have a newly diagnosed lupus patient that you perform an expanded antibody profile,” Elisabet Svenungsson, MD, PhD, an adjunct professor from the Karolinska Institute, in Sweden, told attendees. “This could help to tailor treatment to create better lives in the future. I believe that in the future, that we